Rubicon Research Ltd.

NSE: RUBICON | BSE: 544578 | ISIN: INE506V01022 | Industry: Pharmaceuticals
| Expensive Performer
1170.5000 -10.90 (-0.92%)
NSE Jun 09, 2026 15:31 PM
Volume: 335.8K
 

logo
Rubicon Research Ltd.
18 Nov 2025
1170.50
-0.92%

Outperformance across metrics; stellar start to the post-IPO phase

buy
by Motilal Oswal
Target: 780
Motilal Oswal
Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.
 
Rubicon Research has gained 90.26% in the last 6 Months
More from Rubicon Research Ltd.
Recommended
FY26 sector trends: India Inc grows on stronger demand, better execution
The Baseline | 09 Jun 2026, 06:06PM
Market closes higher on lower oil prices as Iran and Israel halt attacks
Trendlyne Marketwatch | 09 Jun 2026, 03:59PM
CMR Green Tech, Hexagon Nutrition, and three SME IPOs head for listing
| 08 Jun 2026, 06:29PM